2020 ESMO-Asia reported a prospective, non-randomized, open cohort study (Zhu et al., 2021) of Professor Lu Shichun’s team in Beijing 301 Hospital: the study of HCC transformation therapy of TKIs combined with PD-1 inhibitor in the treatment of vascular invasion. Here, PDCD1 is linked to hepatocellular carcinoma.